EUVIMEDEUVIMED entdecken
Crossref

Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study

Joana Camões Neves, Dalila Costa, Margarida Cristiano, Francisco Portela, Ana Rita Fernandes, Samuel Fernandes, Nuno Gonçalves, João Pedro Paulo, Margarida Portugal, Madalina Gututui, Daniela Fernandes, Catarina Costa und 13 weitere

Clinical Gastroenterology and Hepatology · 2026-08

DOI: 10.1016/j.cgh.2026.07.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-08. Verfasst von Joana Camões Neves und 24 weiteren Autor:innen. Beteiligte Einrichtung: Gastroenterology Department, Unidade Local de Saúde Braga, Braga, Portugal; Life and Health Sciences Research Institute (ICVS), School of Medicine, U…. Die Arbeit nennt 53 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Despite the progress in advanced therapies (ATs) for ulcerative colitis (UC), selecting a second-line treatment after failure remains challenging. Recent guidelines recommend upadacitinib, tofacitinib, or ustekinumab as high-efficacy options after prior AT failure. However, real-world comparative data among these 3 agents are lacking. METHODS: This was a retrospective multicenter study (9 centers) including patients with UC who failed ≥1 AT. Patients were stratified into upadacitinib, tofacitinib, or ustekinumab groups and assessed at weeks 16 and 52. The primary outcome was steroid-free clinical remission (SFCR), and secondary outcomes included biochemical and endoscopic remission. Weighted outcomes were analyzed using multivariable logistic regression after propensity score-based inverse probability weighting. RESULTS: We evaluated 312 patients (57.1% female [n = 178]; mean age at diagnosis, 32.6 ± 8.4 years) who initiated upadacitinib (n = 103; 33.0%), tofacitinib (n = 74; 23.7%), or ustekinumab (n = 135; 43.3%). The SFCR rates at weeks 16 and 52 were 47.6% and 75.0% for upadacitinib, 27.0% and 52.4% for tofacitinib, and 26.7% and 53.4% for ustekinumab. The corresponding endoscopic remission rates were 38.1% and 56.8%, 13.2% and 32.7%, and 24.6% and 22.5%. After propensity score-based inverse probability weighting, upadacitinib was associated with higher odds of SFCR compared with tofacitinib (week 16: odds ratio [OR], 2.56; 95% confidence interval [CI], 1.16-5.64; week 52: OR, 3.14; 95% CI, 1.22-8.12) and ustekinumab (week 16: OR, 3.71; 95% CI, 1.88-7.29; week 52: OR, 4.68; 95% CI, 1.96-11.18). Upadacitinib outperformed tofacitinib (week 16: OR, 7.44; 95% CI, 2.09-26.53; week 52: OR, 3.51; 95% CI, 1.22-10.12) and ustekinumab (week 16: OR, 3.34; 95% CI, 1.38-8.09; week 52: OR, 8.69; 95% CI, 3.07-24.60) for endoscopic remission at both timepoints. CONCLUSIONS: Upadacitinib showed higher effectiveness than tofacitinib and ustekinumab in bio-experienced patients with UC.

Schlagwörter

Stichwörter der Autor:innen

Advanced TherapyJAK InhibitorsUlcerative ColitisUstekinumab

Autor:innen und Institutionen

  • Gastroenterology Department, Unidade Local de Saúde Braga, Braga, Portugal; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal. Electronic address: joanacamoesne…
  • Gastroenterology Department, Unidade Local de Saúde Braga, Braga, Portugal; Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Braga, Portugal.
  • Gastroenterology Department, Unidade Local de Saúde Coimbra, Coimbra, Portugal.
  • Gastroenterology Department, Unidade Local de Saúde Santa Maria, Lisboa, Portugal.
  • Gastroenterology Department, Unidade Local de Saúde Santo António, Porto, Portugal; Gastroenterology Department, Instituto Português de Oncologia Francisco Gentil, Porto, Portugal.
  • Gastroenterology Department, Unidade Local de Saúde Santo António, Porto, Portugal.

Zitieren

APA

Camões Neves, J., Costa, D., Cristiano, M., Portela, F., Fernandes, A. R., Fernandes, S., Gonçalves, N., Paulo, J. P., Portugal, M., Gututui, M., Fernandes, D., Costa, C., Madureira, A. M., Marques, J., Conde, P. V., Damasceno, J., Guimarães, A., Rebelo, A., Gonçalves, M., …, & GEDII (Portuguese IBD Group) (2026). Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2026.07.020

Vancouver

Camões Neves J, Costa D, Cristiano M, Portela F, Fernandes AR, Fernandes S, et al. Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study. Clinical Gastroenterology and Hepatology. 2026. doi:10.1016/j.cgh.2026.07.020

BibTeX
@article{CamesNeves2026,
  author = {Camões Neves, Joana and Costa, Dalila and Cristiano, Margarida and Portela, Francisco and Fernandes, Ana Rita and Fernandes, Samuel and Gonçalves, Nuno and Paulo, João Pedro and Portugal, Margarida and Gututui, Madalina and Fernandes, Daniela and Costa, Catarina and Madureira, Ana Margarida and Marques, Jorge and Conde, Patrícia Vaz and Damasceno, José and Guimarães, Andreia and Rebelo, Ana and Gonçalves, Margarida and Soares, João and Mendes, Sofia Silva and Arroja, Bruno and Gonçalves, Raquel and Leal, Tiago and GEDII (Portuguese IBD Group), GEDII (Portuguese IBD Group)},
  title = {Superior Effectiveness of Upadacitinib Over Tofacitinib and Ustekinumab in Bio-Exposed Ulcerative Colitis: The TRIDENT-UC Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2026},
  doi = {10.1016/j.cgh.2026.07.020}
}
Kostenlos starten →